amlodipine besylate; celecoxib · Purple Biotech · NDA 210045
Consensi
Earliest generic entry, as listed · earliest of 3 marketed strengths
14 Jun 2038
No marketed reference-listed strength; date taken from all listed strengths.
Blocked by patent: US 10350171.
Listed patents · 1 unexpired
| Patent | Claims | Expires |
|---|---|---|
| US 10350171 | drug product · sets the listed date | 14 Jun 2038 |
Exclusivities · 0 unexpired
No unexpired exclusivities listed.
Paragraph IV certifications · 0
No Paragraph IV certification listed by FDA for this drug.
The list shows that a generic applicant certified to FDA that a listed patent is invalid or not infringed. It does not show litigation, settlements or launch timing.
Event history
No events yet. The first ingestion only records products entering their 12-month window; changes appear from the next Orange Book update.
Products covered · 3
| NDA · product | Form | Strength | Listed expiry |
|---|---|---|---|
| 210045 · 001 · RLD · discontinued | tablet, oral | EQ 2.5MG BASE;200MG | 14 Jun 2038 |
| 210045 · 002 · RLD · discontinued | tablet, oral | EQ 5MG BASE;200MG | 14 Jun 2038 |
| 210045 · 003 · RLD · discontinued | tablet, oral | EQ 10MG BASE;200MG | 14 Jun 2038 |